Nektar Therapeutics, formerly known as Inhale Therapeutic Systems, is a biopharmaceutical company developing therapeutics for treating cancer, auto-immune disease, and chronic pain using their chemistry technology platform that is headquartered in San Carlos, California and was founded in 1990 by John S. Patton.
On August 28, 2013 Nektar Therapeutics announced raising $25 million in post-IPO equity from AstraZeneca. The agreement was made to have Nektar Therapeutics receive the $25 million when the company's European regulatory filing for one of their anti-constipation drugs called Naloxegol is accepted.
On June 2, 2016 Nektar Therapeutics announced raising $20 million in post-IPO equity from Daiichi Sankyo. The deal gave Daiichi Sankyo the European rights to an experimental cancer treatment frug made by Nektar Therapeutics called etirinotecan pegol (Onzeald).
On April 3, 2018 Nektar Therapeutics announced raising $850 million in post-IPO equity from Bristol-Myers. Bristol-Myers acquired a 4.9% stake in Nektar Therapeutics and plans on helping the company develop and perform clinical trials related to a NKTR-214 persuant.
On July 2, 2001 Nektar Therapeutics announced acquiring Shearwater Corp. for $72.5 million in cash and 4 million shares. At the time of the acquisition Shearwater Therapeutics was valued at approximately $191 million.
On October 21, 2015 Nektar Therapeutics announced acquiring Aerogen, Inc. for $8 million in cash and $24 million in stock. Nektar Therapeutics plans on using the inhaleable liquid drug technology developed by Aerogen, Inc. for making deep-lung drug delivery systems for drugs typically given through injections.